Bioline Rx traded at $1.86 this Wednesday November 4th, decreasing $0.05 or 2.62 percent since the previous trading session. Looking back, over the last four weeks, Bioline Rx lost 19.83 percent. Over the last 12 months, its price fell by 46.55 percent. Looking ahead, we forecast Bioline Rx to be priced at 1.93 by the end of this quarter and at 1.76 in one year, according to Trading Economics global macro models projections and analysts expectations.
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.